Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652288 | 0.76 | HDAC1 (0.63) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL653491 | 0.76 | HDAC1 (0.63) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL4577831 | 0.76 | HDAC2 (0.70) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL4581022 | 0.76 | HDAC2 (0.60) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL4581337 | 0.75 | HDAC2 (0.74) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL651466 | 0.74 | HDAC1 (0.54) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL652289 | 0.74 | HDAC1 (0.54) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL652729 | 0.74 | HDAC1 (0.65) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL4578619 | 0.73 | KCNH2 (0.73) | HDAC1HDAC3KCNH2HDAC2 | |
| SCHEMBL4579437 | 0.73 | HDAC2 (0.61) | HDAC1HDAC3KCNH2HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023924-B1 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-08-03 | — | — | EP | claimed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | claimed |
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | claimed |
| EP-2023924-B1 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8119652-B2 | Aryl-fused spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239849-A1 | Aryl-Fused Spirocyclic Compounds | HDAC1, BRDT, HDAC5 | HDAC1 1/4885HDAC3 5/4885KCNH2 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.